tirzepatide and heart disease New Cleveland Clinic research finds is associated with a 16% lower risk of major kidney complications compared with dulaglutide in people with Type 2 diabetes and heart disease., Tirzepatide Reduces LV Mass and

A 2020 Diabetes Care analysis found that 27% of patients on injectable GLP-1 therapies reported needle-related anxiety, and structured desensitization reduced discontinuation rates by 40% 12

Pfizer's GLP-1 drug isn't on the market yet Like all pharmaceutical companies, Pfizer must go through the approval process before it can market Berobenatide

* Important *

Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results